

#### **Mass General Brigham IRB** Mass General Brigham

399 Revolution Drive, Suite 710 Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

## **Notification of IRB Review**

Protocol #: 2021P002109

August 20, 2021 Date:

Sarpatwari, Ameet, Ph.D, JD To:

BWH

Mass General Brigham > BWH > Medicine > Pharmacoepidemiology

From: Mass General Brigham IRB

399 Revolution Drive, Suite 710

Somerville, MA 02145

Title of Protocol: Risk Evaluation and Mitigation Strategy (REMS) Programs to

Promote Appropriate Medication Use and Knowledge: Physician

Surveys on Experiences with REMS Programs

Version/Number: V1

08/17/2021 Version Date:

Sponsor/Funding/Support Proposal Risk evaluation and mitigation strategy (REMS)

Title: programs to promote appropriate medication use and

knowledge

Principal

Sarpatwari, Ameet

Investigator:

**Immediate** 

Food & Drug Administration (Contracts) Sponsor:

Award

75F40120C00044

Number:

Fund #: 123748

IRB Review Type: Expedited

Expedited Category/ies: (7) Research on individual or group characteristics or behavior (including,

> but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (Note: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101 (b)(2) and

(b)(3). This listing refers only to research that is not exempt.)

IRB Approval Date: 08/20/2021

Approval/Activation

08/20/2021

Date:



Mass General Brigham IRB Mass General Brigham 399 Revolution Drive, Suite 710 Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

**Next Review:** Continuing Review

IRB Expiration Date: 08/20/2022

This project has been reviewed and approved by the **Mass General Brigham IRB**. During the review of this project, the IRB specifically considered (i) the risks and anticipated benefits, if any, to subjects; (ii) the selection of subjects; (iii) the procedures for obtaining and documenting informed consent; (iv) the safety of subjects; and (v) the privacy of subjects and confidentiality of the data.

Please note that if an IRB member had a conflict of interest with regard to the review of this project, consistent with IRB policies and procedures, the member was required to recuse him/herself and, if applicable, leave the room during the discussion and vote on this project except to provide information requested by the IRB.

The following changes to the study staff have been reviewed and approved by the MGB IRB. No further action is required.

### **Study Staff Added:**

- Brown, Beatrice, BWH > Medicine > Pharmacoepidemiology, Research Assistant
- Feldman, William, MD, D.PHIL, MPH, BWH > Medicine > Pharmacoepidemiology, Co-Investigator
- Kesselheim, Aaron, MD, BWH > Medicine > Pharmacoepidemiology, Co-Investigator
- Lee, Su Been, BWH > Medicine > Pharmacoepidemiology, Research Assistant
- Mitra-Majumdar, Mayookha, Mass General Brigham, Regulatory Coordinator/Manager
- Sarpatwari, Ameet, Ph.D, JD, BWH > Medicine > Pharmacoepidemiology, Principal Investigator
- Zakoul, Heidi, BWH > Medicine > Pharmacoepidemiology, Research Assistant

#### **Non-study Staff Added:**

- Bessette, Lily, BWH > Medicine > Pharmacoepidemiology
- Garrison, Rylie, BWH > Medicine > Pharmacoepidemiology
- Seton, Lewis, BWH > Medicine > Pharmacoepidemiology
- Tekle, Winta, BWH > Medicine > Pharmacoepidemiology

### **Financial Delegate:**

• Fund #123748 - Sarpatwari, Ameet

The following documents were reviewed and approved by the IRB. A PDF document listing all documents reviewed and approved by the IRB is available via the "Download" button in Insight.

Protocol Summary 08/17/2021 Detailed Protocol 08/17/2021, V1

#### **ANCILLARY COMMITTEES**



Mass General Brigham IRB

Mass General Brigham 399 Revolution Drive, Suite 710 Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

1. Nursing (BWH): Approved

2. MCA (MGB): Review not needed

As Principal Investigator, you are responsible for ensuring that this project is conducted in compliance with all applicable federal, state and local laws and regulations, institutional policies, and requirements of the IRB, which include, but are not limited to, the following:

- 1. Submission of any and all proposed changes to this project (e.g., protocol, recruitment materials, consent form, status of the study, etc.) to the IRB for review and approval prior to initiation of the change(s), except where necessary to eliminate apparent immediate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB as an unanticipated problem.
- 2. Submission of a continuing review submission or institutional status report as required by the IRB and/or institution to continue the research, and submission of a final report when the project has been closed or completed.
- 3. Submission of any and all unanticipated problems, including adverse event(s) in accordance with the IRB's policy on reporting unanticipated problems including adverse events.
- 4. Obtaining informed consent from subjects or their legally authorized representative prior to initiation of research procedures when and as required by the IRB and, when applicable, documenting informed consent current IRB approved consent form(s) with the IRB-approval stamp in the document footer.
- 5. Informing all investigators and study staff listed on the project of changes and unanticipated problems, including adverse events, involving risks to subjects or others.
- 6. When investigator financial disclosure forms are required, submitting updated financial disclosure forms for yourself and for informing all site responsible investigators, co-investigators and any other members of the study staff identified by you as being responsible for the design, conduct, or reporting of this research study of their obligation to submit updated Investigator Financial Disclosure Forms for this protocol to the IRB if (a) they have acquired new financial interests related to the study and/or (b) any of their previously reported financial interests related to the study have changed.

# IMPORTANT REMINDER: THE IRB HAS THE AUTHORITY TO TERMINATE PROJECTS THAT ARE NOT IN COMPLIANCE WITH THESE REQUIREMENTS.


Questions related to this project may be directed to IRB@partners.org

cc:

Beatrice Brown, Research Assistant, Pharmacoepidemiology, Medicine

Heidi Zakoul, Research Assistant, Pharmacoepidemiology, Medicine

Su Been Lee, Research Assistant, Pharmacoepidemiology, Medicine



Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

Mayookha Mitra-Majumdar, Regulatory Coordinator/Manager, Mass General Brigham Ameet Sarpatwari, Ph.D, JD, Principal Investigator, Pharmacoepidemiology, Medicine Winta Tekle, Pharmacoepidemiology, Medicine Lewis Seton, Pharmacoepidemiology, Medicine Rylie Garrison, Pharmacoepidemiology, Medicine